Adoption of sacubitril/valsartan for the management of patients with heart failure

Circulation: Heart Failure

Volumn 11, Issue 2, 2018, Pages

  Sangaralingham, Lindsey R ^a   Sangaralingham, S Jeson ^a   Shah, Nilay D ^a,b   Yao, Xiaoxi ^a   Dunlay, Shannon M ^a  

^a MAYO CLINIC   (United States)

^b OPTUM   (United States)

Author keywords

Adoption; Drug costs; Heart failure; Sacubitril; Valsartan

Indexed keywords

CARVEDILOL; LISINOPRIL; LOSARTAN; SACUBITRIL PLUS VALSARTAN; SPIRONOLACTONE; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE; VALSARTAN;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG COST; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; ADOLESCENT; ANTAGONISTS AND INHIBITORS; DRUG EFFECT; ECONOMICS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NEPRILYSIN; STROKE VOLUME; TETRAZOLES; TREATMENT OUTCOME; VALSARTAN; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 85049755318     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.117.004302     Document Type: Article

References (33)

1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Fer-ranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neu-mar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: a report from the American Heart Association. Circulation. 2017;135:e146–e603. doi: 10.1161/CIR.0000000000000485.
2. Dunlay SM, Roger VL. Understanding the epidemic of heart failure: past, present, and future. Curr Heart Fail Rep. 2014;11:404–415. doi: 10.1007/ s11897-014-0220-x.
3. Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, Jacobsen SJ. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–350. doi: 10.1001/ jama.292.3.344.
4. Kaye DM, Krum H. Drug discovery for heart failure: a new era or the end of the pipeline? Nat Rev Drug Discov. 2007;6:127–139. doi: 10.1038/ nrd2219.
5. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004. doi: 10.1056/NEJMoa1409077.
6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–2200. doi: 10.1093/ eurheartj/ehw128.
7. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137–e161. doi: 10.1161/CIR.0000000000000509.
8. Sangaralingham LR, Shah ND, Yao X, Roger VL, Dunlay SM. Incidence and early outcomes of heart failure in commercially insured and Medicare advantage patients, 2006 to 2014. Circ Cardiovasc Qual Outcomes. 2016;9:332–337. doi: 10.1161/CIRCOUTCOMES.116.002653.
9. Wallace PJ, Shah ND, Dennen T, Bleicher PA, Bleicher PD, Crown WH. Op-tum Labs: building a novel node in the learning health care system. Health Aff (Millwood). 2014;33:1187–1194. doi: 10.1377/hlthaff.2014.0038.
10. Li Q, Glynn RJ, Dreyer NA, Liu J, Mogun H, Setoguchi S. Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients. Pharmacoepidemiol Drug Saf. 2011;20:700–708. doi: 10.1002/pds.2146.
11. Curtis LH, Whellan DJ, Hammill BG, Hernandez AF, Anstrom KJ, Shea AM, Schulman KA. Incidence and prevalence of heart failure in elderly persons, 1994-2003. Arch Intern Med. 2008;168:418–424. doi: 10.1001/archinternmed.2007.80.
12. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.
13. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother. 2006;40:1280–1288. doi: 10.1345/aph.1H018.
14. Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;133:1115–1124. doi: 10.1161/ CIRCULATIONAHA.115.018622.
15. von Lueder TG, Sangaralingham SJ, Wang BH, Kompa AR, Atar D, Burnett JC Jr, Krum H. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ Heart Fail. 2013;6:594–605. doi: 10.1161/CIRCHEARTFAILURE.112.000289.
16. Luo N, Fonarow GC, Lippmann SJ, Mi X, Heidenreich PA, Yancy CW, Greiner MA, Hammill BG, Hardy NC, Turner SJ, Laskey WK, Curtis LH, Hernandez AF, Mentz RJ, O’Brien EC. Early adoption of sacubitril/valsartan for patients with heart failure with reduced ejection fraction: insights from Get With the Guidelines-Heart Failure (GWTG-HF). JACC Heart Fail. 2017;5:305–309. doi: 10.1016/j.jchf.2016.12.018.
17. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717. doi: 10.1056/NEJM199909023411001.
18. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–551. doi: 10.1056/NEJMoa040135.
19. Marzec LN, Wang J, Shah ND, Chan PS, Ting HH, Gosch KL, Hsu JC, Maddox TM. Influence of direct oral anticoagulants on rates of oral anticoagu-lation for atrial fibrillation. J Am Coll Cardiol. 2017;69:2475–2484. doi: 10.1016/j.jacc.2017.03.540.
20. Yao X, Sangaralingham LR, Ross JS, Shah ND, Talwalkar JA. Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014. Am J Manag Care. 2016;22:e224–e232.
21. Fischer MA, Schneeweiss S, Avorn J, Solomon DH. Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med. 2004;351:2187–2194. doi: 10.1056/NEJMsa042770.
22. Eaddy MT, Cook CL, O’Day K, Burch SP, Cantrell CR. How patient cost-sharing trends affect adherence and outcomes: a literature review. P T. 2012;37:45–55.
23. Gourzoulidis G, Kourlaba G, Stafylas P, Giamouzis G, Parissis J, Maniadakis N. Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure. Health Policy. 2017;121:363–377. doi: 10.1016/j.healthpol.2017.02.008.
24. Packer M. Angiotensin neprilysin inhibition for patients with heart failure: what if sacubitril/valsartan were a treatment for cancer? JAMA Cardiol. 2016;1:971–972. doi: 10.1001/jamacardio.2016.3053.
25. International R. Cardiovascular disease: a costly burden for America. projections through 2035. http://www.heart.org/idc/groups/heart-public/@wcm/@adv/documents/downloadable/ucm_491543.pdf. Accessed January 23, 2018.
26. Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, Rouleau JL, Zile MR, McMurray JJ, Solomon SD. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. JAMA Cardiol. 2016;1:666–672. doi: 10.1001/jamacardio.2016.1747.
27. King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4:392–402. doi: 10.1016/j.jchf.2016.02.007.
28. Ollendorf DA, Sandhu AT, Pearson SD. Sacubitril-valsartan for the treatment of heart failure: effectiveness and value. JAMA Intern Med. 2016;176:249–250. doi: 10.1001/jamainternmed.2015.7661.
29. Sandhu AT, Ollendorf DA, Chapman RH, Pearson SD, Heidenreich PA. Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction. Ann Intern Med. 2016;165:681–689. doi: 10.7326/M16-0057.
30. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353:1471–1480. doi: 10.1056/NEJMsa051989.
31. Banka G, Heidenreich PA, Fonarow GC. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. J Am Coll Cardiol. 2013;61:1440–1446. doi: 10.1016/j.jacc.2012.12.022.
32. Gupta DK, Claggett B, Wells Q, Cheng S, Li M, Maruthur N, Selvin E, Coresh J, Konety S, Butler KR, Mosley T, Boerwinkle E, Hoogeveen R, Ballantyne CM, Solomon SD. Racial differences in circulating natriuretic peptide levels: the atherosclerosis risk in communities study. J Am Heart Assoc. 2015;4:e001831. doi: 10.1161/JAHA.115.001831.
33. Gupta DK, de Lemos JA, Ayers CR, Berry JD, Wang TJ. Racial differences in natriuretic peptide levels: the Dallas Heart Study. JACC Heart Fail. 2015;3:513–519. doi: 10.1016/j.jchf.2015.02.008.